Overview
- A Cell study from Mass General Brigham and Dana-Farber reports that a single injection of a herpes simplex–derived oncolytic virus drove durable T‑cell infiltration into glioblastoma tumors.
- In a 41‑patient Phase I cohort with recurrent disease, survival exceeded historical expectations, with greater benefit observed in patients who had pre‑existing antiviral antibodies.
- Treatment analyses found that cytotoxic T cells located closer to dying tumor cells correlated with longer survival after the oncolytic virus injection.
- MD Anderson’s Clinical Cancer Research report identified blood biomarkers of immunological fitness after Delta‑24‑RGD therapy, and patients receiving subcutaneous interferon gamma were the longest survivors in the TARGET Phase I trial.
- Investigators are testing strategies to enhance and sustain responses, including additional dosing and an ongoing trial of mesenchymal stem cell–based delivery of Delta‑24‑RGD.